Skip to main content

Find Clinical Trials

Home
Conditions
Mantle Cell Lymphoma Refractory

Clinical trial condition

Mantle Cell Lymphoma Refractory

Explore clinical trials studying Mantle Cell Lymphoma Refractory. Study availability and eligibility vary by location and protocol.

3 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Mantle Cell Lymphoma Refractory trial results

Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

NCT05833763

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Peter MacCallum Cancer Centre Parkville, Victoria, Australia

Sir Charles Gairdener Nedlands, Western Australia, Australia

View Trial Details

Completed

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

NCT01389427

Conditions: Mantle Cell Lymphoma Refractory
Locations: CHU de Grenoble MICHALLON Grenoble, Hôpital Nord 217, France

Hôtel Dieu - Université de Nantes Nantes, Place Alexis Ricordeau, France

Hôpital Henri Mondor Créteil, France

CHU de Dijon Dijon, France

View Trial Details

Active, Not Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

NCT05864742

Conditions: Mantle Cell Lymphoma Refractory
Locations: Princess Alexandra Hospital Woolloongabba, Queensland, Australia

Flinders Medical Centre Bedford Park, South Australia, Australia

Peter MacCallum Cancer Centre Parkville, Victoria, Australia

View Trial Details